Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer

Chay, Wen Yee; McCluggage, W. Glenn; Lee, Cheng‐Han; Köbel, Martin; Irving, Julie; Millar, J. L.; Gilks, C. Blake; Tinker, Anna V.

doi:10.1097/igc.0000000000000639

Cited by 30 publications

(21 citation statements)

References 19 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is apparent, the percentage of these women will have disseminated spread of high-grade serious cancer. Based on small series, authors have suggested comprehensive surgical staging including lymphadenectomy [23,24]. This is relatively a new condition with larger case series publication expected over the next few years.…”

Section: Early Stage Ovarian/tubal Cancermentioning

confidence: 99%

The Role of Lymphadenectomy in Ovarian Epithelial Cancer

Nagar¹

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

High-grade serous ovarian/tubal cancer commonly spreads via the peritoneal and lymphatic routes. This chapter discusses the anatomical lymphatic drainage of the ovary and tube with reference to spread from different epithelial ovarian cancer types. The role of lymph node surgery in apparent early stage curative disease will be discussed with reference to staging and directing the need for adjuvant chemotherapy. In advanced disease, the role of lymph node sampling versus systematic dissection surgery as part of cytoreduction is assessed. The result of two randomised controlled trials (RCTs) published on the subject will be analysed along with the ongoing Lymphadenectomy in Ovarian Neoplasia (LION) study. The chapter adopts an evidence-based approach to the role of lymph node surgery in women with epithelial ovarian/tubal cancer.

show abstract

Section: Early Stage Ovarian/tubal Cancermentioning

confidence: 99%

The Role of Lymphadenectomy in Ovarian Epithelial Cancer

Nagar¹

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

show abstract

“…Current evidence indicates the risk of subsequent ovarian HGSC is low (at least within the published follow-up periods), and it is unclear how to predict who will recur/progress. 82–86 Using GEMMs, it is possible to test the effects of various genetic combinations (e.g. Trp53; Brca1; Pten vs. Trp53; Brca1; Rb1 ) on the response of mouse STICs to treatment (e.g.…”

Section: Specific Models and Prevention Studiesmentioning

confidence: 99%

Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention

Karnezis

Cho

2017

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Preclinical models are relatively underutilized and underfunded resources for modeling the pathogenesis and prevention of ovarian cancers.1 Several reviews have detailed the numerous published models of ovarian cancer.2–6 In this review, we will provide an overview of experimental model systems, their strengths and limitations, and use selected models to illustrate how they can be used to address specific issues about ovarian cancer pathogenesis. We will then highlight some of the preclinical prevention studies performed to date and discuss experiments needed to address important unanswered questions about ovarian cancer prevention strategies.

show abstract

“…The third patient had a colon adenocarcinoma and underwent hemicolectomy. No details of further follow-up were available [44].…”

Section: Stic Associated With Other Invasive Malignancies At Primary mentioning

confidence: 99%

“…A recent study from Chay et al published in 2016 reported the follow-up findings of a series of incidental fallopian tube high-grade serous carcinomas and STICs identified in women at low risk of hereditary breast and ovarian carcinoma, undergoing surgery for other indications [44]. Patients with known BRCA1 or BRCA2 mutations, or a family history of ovarian or breast carcinoma before the diagnosis of STIC or HGSC were excluded.…”

Section: Sticclinical Significance Of the Findingmentioning

confidence: 99%

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Weinberger

Bednaříková

Cibula

et al. 2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pathomorphologically and immunohistochemically detectable lesion which biological significance and clinical relevance is unknown. Areas covered: We investigate methods of STIC diagnostics and we present an overview of recent studies and available knowledge on surgical management, adjuvant chemotherapy and subsequent follow-up procedure in women with an isolated STIC. Expert commentary: Patients found to have an incidental STIC lesion should be referred for screening of BRCA1/2 mutation. In absence of an invasive disease, follow-up of patient remains a reasonable choice. A rational scheme should include check-ups every 6 months consisting of gynecological examinations, CA 125 and/or HE4 and pelvic ultrasound examination by an expert sonographer.

show abstract

Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer

Cited by 30 publications

References 19 publications

The Role of Lymphadenectomy in Ovarian Epithelial Cancer

The Role of Lymphadenectomy in Ovarian Epithelial Cancer

Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Contact Info

Product

Resources

About